This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.
On July 26th, Bryan Wesselmann, VP Operations International & Emerging Markets at Rexam Healthcare takes the floor to present on "Innovating for people's health" and discusses industry trends and Rexam's innovative product portfolio.
Always on the cutting edge of innovation, Rexam Healthcare stands for its expertise in designs and manufacturing of packaging, from closures & containers to high-value added drug delivery devices (metering pumps and valves, preservative-free solutions and safety systems among others).
The company is also committed in expanding current facilities to support the fast growing consumer and healthcare markets and, with its recent creation of a dedicated business unit for International and Emerging markets, sets the stage for an increasing presence in these regions.
In India, Rexam's Bangalore plant has been recently expanded with a new 800 square meter clean room, a state-of-the-art new finished goods warehouse that meets the standards prescribed for the regulated market, and extended the range of CRC closures and production tooling to retain leadership position in the ophthalmic market.
Rexam Healthcare's regional Innovation Centers additionally offer a wide range of services to customers - from laboratory and regulatory services to metrology equipment, control of the extractables, user-tests and patient insights and support of customers with innovative "out of the box" solutions, in-house developments and contract manufacturing capabilities.
In the near future, customers can expect launches of devices from our Indian facility for regulated markets demonstrating Rexam Healthcare's strong local technical expertise in this market.
Rexam Healthcare recently announced the launch of its Clic-Loc® closure reference that provides enhanced functionality and aesthetics for industry-leading protection, production efficiency and product differentiation as well as extensions of two of its device-focused European plants.
